arrow
M

Mamoru Watanabe

Juntendo University
H指数:95
被引数:3.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effectiveness, safety, and clinical outcomes of treatment with the oral α4-integrin antagonist carotegrast methyl in patients with active ulcerative colitis: a multicenter observational study (CANAL study)

奥法木单抗(carotegrast methyl)口服α4整合素拮抗剂治疗活动性溃疡性结肠炎的有效性、安全性和临床结局:一项多中心观察性研究(CANAL研究)

2026-09-280
OAAI
IL-22 induces Paneth cell metaplasia in the colonic epithelium of ulcerative colitis, promoting wound healing via REG3A

IL-22在溃疡性结肠炎的结肠上皮中诱导潘氏细胞化生,并通过REG3A促进伤口愈合。

2026-03-280
OAAI
Once-Daily Oral Ozanimod for Japanese Patients With Ulcerative Colitis: Results From the Phase 2/3 J-True North Study
2025-11-010
OAAI
Optimising carotegrast methyl use in ulcerative colitis: patient profiling, predictive biomarkers, and timing of efficacy evaluation (ASPECT study)

优化卡托格斯特甲基在溃疡性结肠炎中的使用:患者特征分析、预测性生物标志物及疗效评估时机(ASPECT研究)

2025-09-220
OAAI
Crosstalk via ICAM-1 enhances supportive phenotype of stellate cells and drives hepatocyte proliferation in iPSC-derived hepatic organoids

通过ICAM-1的串扰增强了星状细胞的支持性表型,并驱动了iPSC源性肝类器官中的肝细胞增殖

2025-09-180
PREAI
Intestinal CD4−CD8αβ−TCRαβ+ T cells function as tolerogenic antigen presenting cells in mice

肠道CD4−CD8αβ−TCRαβ+ T细胞在 mice 中作为耐受原性抗原提呈细胞发挥作用

2025-08-010
OAAI
Hepatitis B Virus-KMT2B Integration Drives Hepatic Oncogenic Processes in a Human Gene-edited Induced Pluripotent Stem Cells-derived Model
2025-01-010
OAAI
Inadequate Efficacy of Biologics for Treating Proximal Ileal Lesions in Crohn’s Disease: A Prospective Multicenter Study

生物制剂治疗克罗恩病近端回肠病变疗效不足:一项前瞻性多中心研究

2024-12-160
PRE
Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study (vol 58, pg 751, 2023)
2024-05-300
OAAI
Identification and epidemiological study of an uncultured flavivirus from ticks using viral metagenomics and pseudoinfectious viral particles
2024-04-300
OAAI
Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies

mirikizumab作为日本中度至重度活动期溃疡性结肠炎患者的诱导和维持治疗的有效性和安全性: 全球3期LUCENT-1和LUCENT-2研究的亚组分析

2024-04-303
OAAI
Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases [IBD]: Real World Results from the International Organization for the study of IBD
2023-10-214
PRE
Integrated safety analysis of filgotinib for ulcerative colitis: Results from SELECTION and SELECTIONLTE

filgotinib治疗溃疡性结肠炎的综合安全性分析: 来自选择和选择的结果

2023-09-185
OAAI
Association of ulcerative colitis symptom severity and proctocolectomy with multidimensional patient-reported outcomes: a cross-sectional study
2023-06-234
OAAI
Clinical Effect of the C-Reactive Protein to Serum Albumin Ratio in Patients with Metastatic Gastric or Gastroesophageal Junction Cancer Treated with Trifluridine/Tipiracil
2023-05-312
OA